Metabolic syndrome reversal criteria — how GLP-1 addresses all 5

This is a textbook metabolic syndrome reversal, and I want to highlight something that gets overlooked: your HOMA-IR going from 8.8 to 1.8 is arguably the most important number in your entire panel.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is calculated as [fasting insulin × fasting glucose] / 405. A value <2.0 indicates normal insulin sensitivity. At 8.8, you were profoundly insulin resistant. At 1.8, you're in the normal range.

This is significant because insulin resistance is the root pathophysiology of metabolic syndrome. Every one of those 5 criteria — central adiposity, elevated TGs, low HDL, hypertension, and hyperglycemia — is downstream of insulin resistance. By restoring insulin sensitivity, tirzepatide addressed the upstream cause rather than treating each downstream symptom individually.

The dual GIP/GLP-1 mechanism of tirzepatide is particularly effective at this because:

• GLP-1 RA: enhances beta-cell function, reduces glucagon, slows gastric emptying
• GIP RA: improves adipocyte insulin sensitivity, enhances lipid storage in subcutaneous (vs. visceral) fat
• Weight loss: reduces hepatic and pancreatic fat, restoring organ-level insulin sensitivity

Your ALT normalization (58 → 22 U/L) strongly suggests you had non-alcoholic fatty liver disease (NAFLD/MASH) at baseline that has substantially resolved. Elevated ALT in the context of metabolic syndrome almost always reflects hepatic steatosis.

I'd be curious to know if you had any imaging done. A FibroScan or ultrasound at baseline vs. now would be very informative. The liver is a critical metabolic organ, and resolution of hepatic steatosis is both a marker and a driver of systemic metabolic improvement.

Your 10-inch waist reduction is also remarkable. Waist circumference is a better proxy for visceral adipose tissue than BMI, and visceral fat is the metabolically active depot that drives inflammatory cytokine production (IL-6, TNF-α, adiponectin deficiency). That reduction likely explains your hsCRP drop.

Great point about the liver. I did have an ultrasound at baseline that showed "moderate hepatic steatosis." My endocrinologist said we'd repeat imaging at the one-year mark, which should be coming up. I'll definitely post the results.

As for the waist measurement: my wife actually measured me at 45.5 inches at baseline (I rounded up to 46 for the post). The 36 inches now was measured at my doctor's office last week. I've gone from a 44 pant to a 34. It's surreal.

To put the OP's results in context of what we'd expect from the trial data, here's how his improvements compare to SURPASS program averages:

His weight loss significantly exceeds trial means, likely due to the addition of regular exercise (30-45 min daily walking) and possibly a higher adiposity-related response to tirzepatide. The TG improvement exceeds means because of the elevated baseline — higher starting values respond more dramatically in absolute terms.